Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling.
暂无分享,去创建一个
Peter Pivonka | Colin R Dunstan | David W. Smith | Bruce S Gardiner | David W Smith | Jan Zimak | T. Martin | P. Pivonka | G. Mundy | N. Sims | B. Gardiner | J. Zimak | Natalie A Sims | C. Dunstan | T John Martin | Gregory R Mundy | T. Martin
[1] L. Hofbauer,et al. The OPG/RANKL/RANK system in metabolic bone diseases. , 2004, Journal of musculoskeletal & neuronal interactions.
[2] Peter Pivonka,et al. Model structure and control of bone remodeling: a theoretical study. , 2008, Bone.
[3] H. Yamazaki,et al. Effects of osteoprotegerin administration on osteoclast differentiation and trabecular bone structure in osteoprotegerin-deficient mice. , 2005, Journal of electron microscopy.
[4] S. Théoleyre,et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.
[5] A R Pettit,et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. , 2001, The American journal of pathology.
[6] Nadine A Defranoux,et al. In Silico Modeling and Simulation of Bone Biology: A Proposal , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[7] G. Rodan,et al. Role of osteoblasts in hormonal control of bone resorption—A hypothesis , 2006, Calcified Tissue International.
[8] N. Bell. RANK ligand and the regulation of skeletal remodeling. , 2003, The Journal of clinical investigation.
[9] L. Hofbauer,et al. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. , 2004, JAMA.
[10] L. Xing,et al. Malignant Autosomal Recessive Osteopetrosis Caused by Spontaneous Mutation of Murine Rank , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[11] L. Xing,et al. Functions of RANKL/RANK/OPG in bone modeling and remodeling. , 2008, Archives of biochemistry and biophysics.
[12] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.
[13] S. Teitelbaum,et al. Bone resorption by osteoclasts. , 2000, Science.
[14] Svetlana V Komarova,et al. Mathematical model predicts a critical role for osteoclast autocrine regulation in the control of bone remodeling. , 2003, Bone.
[15] Vincent Lemaire,et al. Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. , 2004, Journal of theoretical biology.
[16] Sundeep Khosla,et al. The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[17] N. Maalouf,et al. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. , 2007, The Journal of clinical endocrinology and metabolism.
[18] A. Parfitt. Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. , 2002, Bone.
[19] S. Morony,et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[20] Martin Tj. Paracrine regulation of osteoclast formation and activity: milestones in discovery. , 2004 .
[21] B. L. Riggs,et al. Drugs Used to Treat Osteoporosis: The Critical Need for a Uniform Nomenclature Based on Their Action on Bone Remodeling , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[22] J. Aubin,et al. Advances in the osteoblast lineage. , 1998, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[23] K Yano,et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. , 1998, Biochemical and biophysical research communications.
[24] Jacques P. Brown,et al. Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[25] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.